atazanavir + tenofovir

Atazanavir + tenofovir is a combination of two antiretroviral drugs used in the treatment of HIV-1 infection. Atazanavir is a protease inhibitor that prevents viral replication by inhibiting the HIV protease enzyme, which is essential for the maturation of infectious virus particles. Tenofovir, typically administered as its prodrug form tenofovir disoproxil fumarate (TDF), is a nucleotide reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase and hepatitis B polymerase by competing with natural deoxyribonucleotide substrates and causing DNA chain termination. The combination is used as part of highly active antiretroviral therapy (HAART) regimens for both treatment-naive and treatment-experienced patients with HIV infection[4][6]. When co-administered, pharmacokinetic interactions occur: atazanavir levels are reduced while tenofovir levels are increased, necessitating ritonavir boosting to maintain efficacy and minimize toxicity[3][5]. Atazanavir was developed by Bristol Myers Squibb; tenofovir was developed by Gilead Sciences.

Other names

atazanavir disulfate + tenofovir disoproxil fumarate